{
    "nctId": "NCT00084396",
    "briefTitle": "Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer",
    "officialTitle": "A Phase 2 Trial Of 4 Months Preoperative Letrozole 2.5 mg Daily For Postmenopausal Women With Estrogen Receptor Positive And/Or Progesterone Receptor Positive T2, T3, T4a-c, N0-2, M0 Breast Cancer- Novel Biomarkers for Aromatase Inhibitor Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 115,
    "primaryOutcomeMeasure": "Predictive model for response as assessed by gene expression profiling",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed infiltrating adenocarcinoma of the breast by core needle biopsy\n\n  * Clinical stage T2-T4a-c, N0-2, M0\n* Palpable and measurable disease\n* Previously untreated disease\n* Benefits from neoadjuvant therapy that would improve surgical outcome AND meets criteria for 1 of the following:\n\n  * Marginal candidate for lumpectomy (e.g., lumpectomy feasible but patient at risk for positive margins or poor cosmetic outcome) AND patient desires breast-conserving surgery\n  * Ineligible for lumpectomy due to size of primary tumor, but modified radical mastectomy feasible AND patient desires breast-conserving surgery\n  * Inoperable disease AND systemic therapy required for disease to become operable by modified radical mastectomy\n* Bilateral primary tumors allowed provided both tumors are consistent with entry criteria\n* No inflammatory carcinoma (defined as peau d' orange affecting at least one third of the breast)\n\n  * Direct extension of the tumor to the skin allowed\n* No metastatic breast disease, except isolated ipsilateral supraclavicular lymphadenopathy\n* Hormone receptor status:\n\n  * Estrogen- and/or progesterone-receptor positive disease based on 10% or more nuclear staining of the invasive component of the tumor\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Postmenopausal\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, defined as meeting 1 of the following criteria:\n\n  * Cessation of menstrual periods for at least 1 year\n  * Bilateral surgical oophorectomy\n  * Follicle-stimulating hormone and estradiol levels in the postmenopausal range\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* No severe liver dysfunction that would preclude study participation\n\nRenal\n\n* Not specified\n\nOther\n\n* Willing and able to provide biopsy material\n* Willing to undergo breast surgery after neoadjuvant treatment\n* No condition (e.g., confusion, infirmity, or alcoholism) that would preclude study compliance\n* No other concurrent active and progressive invasive malignancies\n* No other concurrent severe disease that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No concurrent immunotherapy or biological response modifiers for breast cancer\n\nChemotherapy\n\n* No prior chemotherapy for breast cancer\n* No concurrent chemotherapy for breast cancer\n\nEndocrine therapy\n\n* At least 2 weeks since prior hormone replacement therapy or phytoestrogenic herbal, alternative, or over-the-counter (OTC) sex hormone remedies\n* No prior hormonal agents for breast cancer\n* No prior aromatase inhibitors, tamoxifen, raloxifene, or other antiestrogen or selective estrogen receptor modulators\n* No concurrent drugs known to affect sex hormone status, including hormone replacement therapy or phytoestrogenic herbal, alternative, or OTC remedies\n* No other concurrent endocrine therapy for breast cancer\n\nRadiotherapy\n\n* No prior radiotherapy for breast cancer\n* No concurrent radiotherapy for breast cancer\n\nSurgery\n\n* Prior sentinel node biopsy allowed\n* No other concurrent surgery for breast cancer\n\nOther\n\n* More than 30 days since prior non-approved or experimental drugs\n* Concurrent bisphosphonates for osteoporosis allowed\n* No other concurrent treatment for breast cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}